Premenstrual Dysphoric Disorder Clinical Trial
Official title:
A Phase 3 Study of the Use of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
The objective of this study is to evaluate the effectiveness and safety in double-blind, randomized, placebo-controlled clinical trials of self administered PH80 intranasal spray for the acute management of cycle related symptoms in women who regularly experience premenstrual dysphoric disorder (PMDD).
Premenstrual disorders are characterized by negative mood, behavioral, and physical symptoms
that occur consistently for several days to two weeks before menses, that can disrupt normal
functioning, and that subside during the postmenstrual phase of the cycle. Marked
irritability, marked depressed mood, marked anxiety, overeating of specific food cravings,
mood swings, lack of energy, and pain are among the most common symptoms of moderate to
severe premenstrual disorders.
It is estimated that 75% women of reproductive age (menarche to perimenopause) experience
physical and behavioral symptoms premenstrually and in 40% women symptoms are intense
(moderate to severe) and require medical attention. For 3-8 % women premenstrual symptoms
are severe enough to interfere with work and interpersonal relationships. Premenstrual
Dysphoric Disorder (PMDD) as defined by the Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV) research criteria, represents the more severe and
disabling end of the premenstrual disorders spectrum. For women with severe premenstrual
symptoms or PMDD, these symptoms are bothersome enough to produce an impact on psychological
and/or occupational functioning, and professional attention is required.
Selective serotonin reuptake inhibitors (SSRIs) fluoxetine, sertaline and paroxetine have
been approved by the United States Food and Drug Administration (FDA) as a chronic treatment
for PMDD, however the use of SSRIs significantly increases the risk of suicide in
adolescents and young adults. Antidepressants are also associated with significant relapse
during short and long term treatment of PMDD. Contraceptives are also prescribed to treat
moderate and severe premenstrual symptoms, but besides the severe adverse effects
(drospirenone and ethinyl estradiol) they re not the treatment choice for women willing to
become pregnant.
Pherin Pharmaceuticals synthesized a number of pherines and screened them for biologic
activity in vitro. PH80 is a pherine shown to bind to a subset of peripheral receptors in
nasal chemosensory neurons. Pherines such as PH80 are thought to exert their activity by
rapid stimulation of the hypothalamus, which does not require systemic uptake and
distribution. PH80 is being investigated as a potential treatment in women that suffer the
cycle related symptoms of Premenstrual Dysphoric Disorder.
Each single administration of PH80 to be tested in this study will deliver a similar amount
of PH80 (800 nanogram) to the nasal passages as was found in previous investigations (Pherin
Clinical Study #PH80 CL003, #PH80 CL015 and #PH80 CL016) to improve premenstrual symptoms in
PMDD patients when administered intranasally on an acute basis.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03862469 -
Premenstrual Hormonal and Affective State Evaluation (PHASE) Project
|
N/A | |
Active, not recruiting |
NCT00536198 -
Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder
|
N/A | |
Completed |
NCT03449979 -
Single Session of tACS in a Depressive Episode
|
N/A | |
Completed |
NCT00516113 -
A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria
|
Phase 4 | |
Recruiting |
NCT05098574 -
Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder
|
Phase 2 | |
Withdrawn |
NCT04123483 -
EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders
|
Phase 4 | |
Completed |
NCT00518570 -
Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)
|
N/A | |
Terminated |
NCT02362191 -
Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD
|
N/A | |
Completed |
NCT00678574 -
The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder
|
Phase 4 | |
Active, not recruiting |
NCT05327075 -
Premenstrual Dysphoric Disorder:Knowledge,Attitude and Practice Among Egyptian Females
|
||
Not yet recruiting |
NCT02448836 -
Deep Transcranial Magnetic Stimulation (dTMS) for the Treatment of Premenstrual Dysphoric Disorder (PMDD)
|
N/A | |
Completed |
NCT01799733 -
Alternative Treatments for Premenstrual Dysphoric Disorder
|
N/A | |
Completed |
NCT06227676 -
Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02508103 -
Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study
|
Phase 2/Phase 3 | |
Completed |
NCT00927095 -
Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)
|
Phase 4 | |
Completed |
NCT00089414 -
Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives
|
Phase 2 | |
Not yet recruiting |
NCT06462391 -
Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms
|
N/A | |
Completed |
NCT01875718 -
A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)
|
Phase 1/Phase 2 | |
Completed |
NCT06136104 -
The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms
|
N/A | |
Completed |
NCT01385709 -
The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels
|
N/A |